Objective To explore the effect of multimodal interventions in improving the compliance rate of core infection control measures on reducing the incidence rate of vessel catheter associated infection (VCAI). Methods Inpatients with intravascular catheters in 5 departments with high rates of vascular catheterization and infection of Dongguan People’s Hospital between January 2021 and December 2022 were selected. According to the hospital stay, patients were divided into a pre-intervention group (January to December 2021) and a post-intervention group (January to December 2022). The core infection control measures assessment pass rates of medical staff between the two periods and the differences in the incidence rate of VCAI, average catheterization days, and catheterization rate before and after intervention in both groups were compared. Results A total of 8174 patients were included. Among them, there were 3915 patients in the pre-intervention group and 4259 patients in the post-intervention group. In the pre-intervention group, the total length of hospital stay was 122885 days, the total number of catheterization days was 48028 days, and 28 cases of VCAI occurred. In the post-intervention group, the total length of hospital stay was 126966 days, the total number of catheterization days was 51253 days, and 12 cases of VCAI occurred. After intervention, the compliance rate of VCAI core infection control measures was improved [69.21% (2907/4200) vs. 91.24% (3832/4200); χ2=642.090, P＜0.001], the pass rate of medical staff’s core infection control measures assessment was improved [53.33% (128/240) vs. 91.67% (220/240); χ2=88.443, P＜0.001], the catheterization rate was increased [39.08% (48028/122885) vs. 40.37% (51253/126966); χ2=42.979, P<0.001], and the incidence rate of VCAI was reduced [0.58‰ (28/48028) vs. 0.23‰ (12/51253); incidence-rate ratios =0.40, 95% confidence interval (0.20, 0.79), P=0.008]. Conclusions Improving the compliance rate of VCAI core infection control measures through multimodal interventions can significantly improve the passing rates of core infection control measures of medical staffs. This will help to reduce the incidence of VCAI and ensuring patient safety, provide evidence-based support for the prevention and control of VCAI.
ObjectiveTo provide a basis for timely adjustment of cancer prevention and control measures in China through timely understanding of the latest 2022 global cancer statistics reported in the CA: A Cancer Journal for Clinicians published “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. MethodsThe statistical data of GLOBOCAN in 2022 were systematically analyzed and the incidence and mortality of cancer by age, sex, type, and region were comprehensively interpreted. The changing trends in cancer were compared between China and the rest of the world, and the potential risk factors as well as current cancer prevention and control measures were summarized. Results① Globally, for both sexes combined, there were an estimated 19.976 million new cases and 9.744 million cancer deaths in 2022. The age-standardized incidence rate (ASIR) was 196.9 per 100 000 and the age-standardized mortality rate (ASMR) was 91.7 per 100 000 in 2022. The ASIR of all cancers was highest in Europe (268.1 per 100 000) and lowest in South-East Asia (109.6 per 100 000), as well as the ASMR of all cancers was highest in Europe (106.3 per 100 000) and lowest in South-East Asia (71.0 per 100 000). The top three cancer types of newly diagnosed cancer cases were lung, breast, and colorectal cancer, while the top three leading causes of cancer deaths were lung, colorectal, and liver cancer. The incidence and mortality rates of all cancers increased with advancing age. The numbers of newly diagnosed cancer cases and cancer deaths, as well as the age-standardized rates were consistently higher among men compared to women. The lung cancer and breast cancer ranked first in terms of newly diagnosed cancer cases among men and women, respectively. Consistently, the lung cancer and breast cancer were also the leading causes of cancer-related deaths among men and women, respectively. ② In China, there were an estimated 4.825 million new cases and 2.574 million cancer deaths. The ASIR was 201.6 per 100 000 and the ASMR was 96.5 per 100 000 in 2022. The ASIR and ASMR both ranked 65th out of 185 countries. The top three cancer types among newly diagnosed cases were lung cancer, colorectal cancer, and thyroid cancer, while the top three leading causes of cancer deaths were lung cancer, liver cancer, and gastric cancer. ConclusionsThe cancers incidences and deaths worldwide in 2022 have declined from that in 2020 (196.9 per 100 000 versus 201.0 per 100 000, 91.7 per 100 000 versus 100.7 per 100 000, respectively). Lung cancer is the leading type of newly diagnosed cancer both in China and globally. However, the second and third most common cancers in China differ from the global picture. In China, colorectal cancer and thyroid cancer take the second and third spots, respectively; Whereas globally, breast cancer and colorectal cancer occupy these positions. Lung cancer is the first ranked leading cause of death in both China and globally. However, there are differences in the second and third most common causes. In China, liver cancer and gastic cancer take the second and third spots, respectively; While globally, colorectal cancer and liver cancer occupy these positions. This study analyzes the characteristics of the disease burden of cancer in China by comparing the epidemiological features of cancer in China and worldwide, aiming to provide scientific evidences for developing comprehensive cancer prevention and control measures tailored specifically to China’s national conditions.
Objective To summary the incidence rate and trends of cancers in China. MethodsBy compiling and analyzing the Chinese Cancer Registry Annual Report from 2008 to 2021, we summarized the regional and population distribution characteristics of overall and high-incidence rate cancers in China and analyzed influencing factors. ResultsFrom 2005 to 2018, the overall crude incidence of cancers in China showed a continuous upward trend. The incidence rate in the eastern region (incidence rate was 353.26/100 000 in 2018, the following data were crude incidence rate in 2018) was significantly higher than those in the central (269.47/100 000) and western regions (253.71/100 000), while the incidence rates in the central and western regions were closer. 2005–2018, the incidence rates of male was higher than that of female, and the population aged 80 years old or older (2 741.02/100 000) had the highest incidence rate of cancers, and the incidence rate of people aged 0–14 years old (41.38/100 000) was the lowest. From 2005–2018 (except for 2009), lung cancer (65.05/100 000), gastric cancer (27.03/100 000), liver cancer (27.42/100 000), colorectal cancer (30.51/100 000), and breast cancer (43.02/100 000) were the top 5 highest incidence rates of China’s cancers, of which lung cancer ranked the first in different regions, and the ranking of other cancers varied in different regions. The top 5 cancers in males’ incidence rates from 2005 to 2018 were lung cancer (83.45/100 000), gastric cancer (37.12/100 000), liver cancer (40.02/100 000), colorectal cancer (35.32/100 000) and esophageal cancer (26.30/100 000); the top 5 cancers in females’incidence rates had changed a lot in different years, breast cancer, lung cancer, colorectal cancer, gastric cancer, liver cancer, thyroid cancer and cervical cancer had all been in the top 5, for example, in 2018, the top 5 cancers in female were lung cancer (46.10/100 000), breast cancer (43.02/100 000), colorectal cancer (25.56/100 000), thyroid cancer (24.60/100 000) and cervical cancer (18.10/100 000).ConclusionsThe crude incidence rate of cancers in China continues to rise, with the cancer spectrum showing new characteristics that combine high-incidence rate cancers in developed countries (e.g., breast cancer, colorectal cancer) with common cancers in developing countries (e.g., gastric cancer, liver cancer). The situation of cancer prevention and control remains challenging.
ObjectiveTo analyze and compare the incidence, mortality, temporal trends, and cancer spectrum differences between China and the United States (US), providing theoretical support for cancer prevention and control in China. MethodsAge standardized incidence rate (ASIR), age standardized mortality rate (ASMR), and cancer site composition were extracted from GLOBOCAN, Cancer Statistics 2025, the China Cancer Registry Annual Report, and other epidemiological sources. Spatial (urban-rural, sex specific) and temporal distributions were described, and average annual growth rate (AAGR) were calculated. ResultsFrom 2005 onward, China exhibited a modest rise in ASIR, whereas the US showed a decline (AAGR: 0.58 vs –0.42); nevertheless, China’s overall incidence remained lower (2022 ASIR = 201.61/100 000) than that of the US (303.60/100 000). Both countries experienced decreasing ASMR (AAGR: –1.03 vs –1.72). In both nations, male ASIR and ASMR were higher than female. Since 2005, the top three US cancers had remained prostate (men) or breast (women), lung and colorectal cancer. In China, incidences of lung, colorectal, female breast and thyroid cancers had continued to rise, while stomach and liver cancer incidences had declined yet still rank high among men. Urban ASIR in China exceeded rural rates, whereas rural ASMR was higher than urban counterparts. ConclusionsAccelerating population ageing and lifestyle transitions have driven an upward incidence trend in China, accompanied by a shift towards a mixed pattern of traditional and emerging cancer risks. Drawing on US experience, China should intensify tobacco control measures, expand organized screening and early detection programs, implement comprehensive interventions for priority cancers, strengthen primary level capacity and improve treatment access in rural areas, thereby establishing a more effective national cancer prevention and control system.
ObjectiveTo investigate the relationship between lumbar facet joint degeneration of each segment and spine-pelvic sagittal balance parameters. MethodsA retrospective analysis was made the clinical data of 120 patients with lumbar degenerative disease, who accorded with the inclusion criteria between June and November 2014. There were 58 males and 62 females with an average age of 53 years (range, 24-77 years). The disease duration ranged from 3 to 96 months (mean, 6.6 months). Affected segments included L3, 4 in 32 cases, L4, 5 in 47 cases, and L5, S1 in 52 cases. The CT and X-ray films of the lumbar vertebrae were taken. The facet joint degeneration was graded based on the grading system of Pathria. The spine-pelvic sagittal balance parameters were measured, including lumbar lordosis (LL), upper lumbar lordosis (ULL), lower lumbar lordosis (LLL), pelvic incidence (PI), pelvic tilt (PT), and sacral slope (SS). According to normal range of PI, the patients were divided into 3 groups: group A (PI was 1ess than normal range), group B (PI was within normal range), and group C (PI was more than normal range). The facet joint degeneration was compared;according to the facet joint degeneration degree, the patients were divided into group N (mild degeneration group) and group M (serious degeneration group) to observe the relationship of lumbar facet joint degeneration of each segment and spine-pelvic sagittal balance parameters. ResultsAt L4, 5 and L5, S1, facet joint degeneration showed significant difference among groups A, B, and C (P<0.05), more serious facet joint degeneration was observed in group C;no significant difference was found in facet joint degeneration at L3, 4 (P>0.05). There was no significant difference in the other spine-pelvic sagittal balance parameters between groups N and M at each segment (P>0.05) except for PT (P<0.05). ConclusionPI of more than normal range may lead to or aggravate lumbar facet joint degeneration at L4, 5 and L5, S1;PT and PI are significantly associated with facet joint degeneration at the lower lumbar spine.
ObjectiveTo interpret and compare the epidemiologic data of gastric cancer incidence and mortality in the world and China during 2018–2022, and to evaluate the disease burden of gastric cancer in China. MethodBased on the GLOBOCAN 2018–2022 cancer registry data released by the International Agency for Research on Cancer (IARC), both the crude and the age-standardized incidence and mortality data of gastric cancer were retrieved, while the situation of gastric cancer incidence and mortality was compared between China and the world. ResultsComparing with the global incidence and mortality of gastric cancer, although the incidence and mortality of gastric cancer in China showed a consistently declining trend, the numbers of incident cases and deaths kept the greatest in the world, which was one of the important cancer disease burdens in China. In the 2022 report, there were 968 350 incident cases and 660 175 deaths from gastric cancer worldwide. Therein, China had the greatest number of incident cases and deaths from gastric cancer, i.e. 358 000 (37.0% of the global total) and 260 000 (39.5% of the global total), respectively. The age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) for gastric cancer worldwide were 9.2/100 000 and 6.1/100 000, respectively; in China, the ASIR and ASMR were 13.7/100 000 and 9.4/100 000, respectively, both of which were higher than the global average levels. Similarly, in terms of the assessment on population morbidity index (PMI), the risk of death from gastric cancer in China appeared a declining trend, but it was still at a higher level compared to the global average. In very high and high human development index (HDI) countries/regions, the ASIR and ASMR of gastric cancer were higher than those in medium and low HDI countries/regions, while the trend was similar when stratified by gross national income (GNI) per capita. In countries/regions with very high HDI or high GNI per capita, the PMI was lower than those in other stratified countries/regions. There were certain geographic disparities in the ASMR of gastric cancer in China. The western region, especially the Qinghai-Tibet Plateau region, had the heaviest burden of gastric cancer deaths, and a few provinces in the central and eastern regions also faced a heavy burden of gastric cancer deaths. Similar to the global situation, the incidence and death risk of gastric cancer were higher among males in China. The ASIR and ASMR in males were more than two times to those in females, while the PMI in males and females were comparable. Globally, subpopulation ≥50 years old entered the age-groups with high incidence of gastric cancer, while in China, the high incidence age-groups were since 45 years old. ConclusionsThe burden of gastric cancer is still heavy in China and higher than the global level. HDI, GNI per capita, regional distribution, gender, and age are associated with the incidence and death risks of gastric cancer. The key points of gastric cancer prevention and control in China should be focused on raising awareness of cancer prevention among the public population, establishing tertiary prevention system in subnational areas, supporting large-scale population screening projects, systematically surveilling the high-risk subpopulation, promoting standardized cancer diagnosis and treatment, and whole-life managing and caring cancer patients.
"Global cancer statistics 2022" based on the latest GLOBCAN data from the International Agency for Research on Cancer (IARC) was recently released, providing a systematic analysis of the incidence and mortality of 36 types of cancer across 185 countries worldwide. The international burden of cancer is expected to continue to increase over the next 30 years, posing a severe public health and social challenge for many countries, including China. This article offers a key point interpretation of the "Global cancer statistics 2022", focusing on the evolution of cancer epidemiology and future development trends. The aim is to broaden the international perspective on cancer prevention and treatment, with the hope of providing reference and guidance for cancer prevention and treatment efforts in our country.
In 2022, the National Cancer Center (NCC) of China reported the nationwide statistics of 2016 using population-based cancer registry data from all available cancer registries in China, which was mainly about the cancer incidence and mortality. Cancer remains a major health problem currently in our country and requires long term cooperation to deal with. This article provided a key point interpretation and analysis of cancer prevalence data in China, and provided an analysis of several main risk factors for cancer, which was conducive to the development of cancer prevention and control programs in different regions.
Objective To explore the current status and changing trends of the disease burden of traumatic brain injury (TBI) in China from 1990 to 2023, and to quantitatively assess the impact of different influencing factors on this disease burden, thereby providing references for the prevention of TBI. Methods Based on the 2023 Global Burden of Disease (GBD) study, indicators including incidence and years lived with disability (YLDs) were used to analyze the status and changing trends of TBI disease burden in China from 1990 to 2023. Additionally, the decomposition method established by Gupta was adopted to quantify the effects of population growth, population aging, age-specific incidence rate, and disease severity on YLDs. ResultsFrom 1990 to 2023, the age-standardized incidence rate and YLD rate of TBI in China showed an overall upward trend, with a significant downward trend between 2015 and 2020, followed by a resumption of upward trend after 2020. The disease burden of TBI in males was higher than that in females, with a larger increase amplitude. The elderly population had higher TBI incidence rate and YLD rate, also with a larger upward amplitude. Falls were the main cause of TBI in China, and the changing trend of the disease burden caused by falls was consistent with the overall trend of TBI disease burden; meanwhile, the elderly population bore a relatively high disease burden from falls. Taking 1990 as the baseline, the growth rates of YLDs in males and females in 2023 were 101.54% and 101.40%, respectively. For males, the proportions of YLDs growth attributed to population growth, population aging, age-specific incidence rate, and disease severity were 26.91%, 49.62%, 37.74%, and –12.73%, respectively; for females, the corresponding proportions were 28.85%, 57.69%, 27.65%, and –12.79%. ConclusionFrom 1990 to 2023, population aging had a significant impact on the disease burden of TBI in China. Strengthening the prevention and control of falls and paying close attention to males and the elderly population should be the key focuses of TBI prevention and control work in China in the future.
Colorectal cancer is the third most frequently diagnosed cancer and the second leading cause of cancer death worldwide. In recent years, with the development and change of society and economy, the epidemiological characteristics of colorectal cancer related to geographic economy and health resources have caused its incidence to show a trend of regional differentiation. At present, the diagnosis, treatment, prevention and control of colorectal cancer in China are still facing great challenges, therefore, summarizing the risk factors related to the incidence of colorectal cancer in China from the global epidemiological characteristics of colorectal cancer can further guide the prevention, control and clinical diagnosis and treatment of colorectal cancer in China, and is of great significance to improve the heavy burden of colorectal cancer. Therefore, this paper discusses the epidemiological characteristics of colorectal cancer in recent years and the screening policies in different regions based on the report of the International Agency for Research on Cancer and related studies, so as to provide the relevant basis for the prevention and control of colorectal cancer in the new situation in the future.